These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38383267)

  • 1. Immune thrombocytopenia in systemic lupus erythematosus: Prevalence, risk factors, and a novel predictive model for risk assessment.
    Cornudella Lema J; Sánchez-González B; Carrión-Barberà I; Vázquez Montes de Oca S; García Pallarols F; Salman-Monte TC
    Med Clin (Barc); 2024 May; 162(10):461-469. PubMed ID: 38383267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study.
    Zhu FX; Huang JY; Ye Z; Wen QQ; Wei JC
    Ann Rheum Dis; 2020 Jun; 79(6):793-799. PubMed ID: 32241798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Childhood-onset systemic lupus erythematosus and immune thrombocytopenia: Prevalence and risk factors.
    Kittivisuit S; Vachvanichsanong P; McNeil E; Chotsampancharoen T
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29146. PubMed ID: 34047041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case-control study in Chinese children.
    Song Y; Zhang Y; Li Z; Liu J; Xiao J; Song H
    Ann Hematol; 2022 Jul; 101(7):1447-1456. PubMed ID: 35532821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Idiopathic thrombocytopenic purpura as first manifestation of systemic lupus erythematosus lupus].
    Balsalobre Aznar J; Herráez Herrera P; Porta Etessam J; Torres Martín C; Bermell Serrano JC; Núñez López R; Mateo Bernardo I; Padrino Martínez JM; Morillas López L
    An Med Interna; 1999 Dec; 16(12):611-4. PubMed ID: 10686711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia.
    Ahn SM; Choi EJ; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
    Arthritis Res Ther; 2022 Sep; 24(1):213. PubMed ID: 36068638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of systemic lupus erythematosus in patients with immune thrombocytopenic purpura: A systematic meta-analysis.
    Pamuk ON; Ali SM; Hasni S
    Autoimmun Rev; 2023 Apr; 22(4):103297. PubMed ID: 36781038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors of systemic lupus erythematosus in patients with primary immune thrombocytopenia: a systematic review and meta-analysis.
    Zhou EM; Shen H; Wang D; Xu W
    PeerJ; 2024; 12():e17152. PubMed ID: 38666084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria.
    Mosca M; Costenbader KH; Johnson SR; Lorenzoni V; Sebastiani GD; Hoyer BF; Navarra S; Bonfa E; Ramsey-Goldman R; Medina-Rosas J; Piga M; Tani C; Tedeschi SK; Dörner T; Aringer M; Touma Z
    Arthritis Rheumatol; 2019 Jan; 71(1):91-98. PubMed ID: 30035365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment with belimumab for immune thrombocytopenia associated with systemic lupus erythematosus: A report of two cases.
    Nakayama K; Tamimoto Y; Nakayama T
    Mod Rheumatol Case Rep; 2023 Dec; 8(1):69-73. PubMed ID: 37718578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review.
    Garra W; Carmi O; Kivity S; Levy Y
    Medicine (Baltimore); 2023 Feb; 102(6):e32949. PubMed ID: 36820549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus.
    Nishino A; Katsumata Y; Kawasumi H; Hirahara S; Kawaguchi Y; Yamanaka H
    Lupus; 2019 Jul; 28(8):986-994. PubMed ID: 31246559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse.
    Cimé-Aké E; Barrera-Vargas A; Demichelis-Gómez R; Ramírez-Alemón M; Rull-Gabayet M
    Clin Rheumatol; 2024 Aug; 43(8):2521-2532. PubMed ID: 38916764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study.
    Liu Y; Chen S; Sun Y; Lin Q; Liao X; Zhang J; Luo J; Qian H; Duan L; Shi G
    Medicine (Baltimore); 2016 Dec; 95(50):e5565. PubMed ID: 27977588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antiphospholipid antibodies and the risk of thrombosis: a comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome].
    Moulis G; Delavigne K; Huguet F; Fortenfant F; Beyne-Rauzy O; Adoue D
    Rev Med Interne; 2011 Dec; 32(12):724-9. PubMed ID: 21864953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura.
    Hazzan R; Mukamel M; Yacobovich J; Yaniv I; Tamary H
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):657-9. PubMed ID: 16933242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of Antiphospholipid Antibodies as a Risk Factor for Thrombotic Events in Patients with Connective Tissue Diseases and Idiopathic Thrombocytopenic Purpura.
    Habe K; Wada H; Matsumoto T; Ohishi K; Ikejiri M; Matsubara K; Morioka T; Kamimoto Y; Ikeda T; Katayama N; Mizutani H
    Intern Med; 2016; 55(6):589-95. PubMed ID: 26984073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
    Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
    Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients.
    Ramos-Casals M; Campoamor MT; Chamorro A; Salvador G; Segura S; Botero JC; Yagüe J; Cervera R; Ingelmo M; Font J
    Lupus; 2004; 13(10):777-83. PubMed ID: 15540510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.